University of Health Sciences, Ankara Numune Research and Training Hospital, Department of Urology, Ankara, Turkey .
University of Health Sciences, Ankara Numune Research and Training Hospital, Department of Medical Biochemistry, Ankara, Turkey .
Urol J. 2021 Oct 16;19(3):196-201. doi: 10.22037/uj.v18i.6626.
Prostate canceris the most commonly diagnosed type of cancer and one of the leading causes of cancer-related death in men.Numerous efforts have been made to improve existing diagnostic methods and develop a new biomarker to identify patients with prostate cancer. In line with current literature, we preferred new serum-based biochemical markers as Pentraxin-3, Fetuin-A and Sirtuin-7 in the present study.
A total of 174 patients aged 42-76 years were included in the study. Patients with prostate cancer (n=38) were enrolled as Group 1 and patients with benign prostatic hyperplasia (n=136) as Group 2. The serum levels of Pentraxin-3, Fetuin-A and Sirtuin-7 levels were compared between the groups.
The mean age of the patients was 61.9±7.6 years (p= .001). The mean serum Prostate Specific Antigen levels 32.0±59.6 (2.6-336) ng/mL and 10.0±11.3 (2.5-77.4) ng/mL in Group 1 and 2, respectively (p= .029). The mean serum levels of Pentraxin-3 and Fetuin-Ain Group 1 were statistically significantlydifferent from Group 2(3.3±4.4 ng/mL vs 1.8±2.4 ng/mL, p= .002 and 466.8±11.0 µg/mL vs 513.3±11.0 µg/mL,p= .041,respectively). There was no significant difference between Group 1 and 2 according to serum levels of Sirtuin-7 (12.7±8.2 ng/mL vs 12.7±12.4 ng/mL respectively, p= .145).
Pentraxin-3, Fetuin-A and Sirtuin-7 may be effective in the diagnosis of prostate cancerin light of the current literature.In this study, it was found that Pentraxin-3 and Fetuin-A were significantly different in the diagnosis of prostate cancer.Larger-scale prospective studies are needed to determine the importance of Pentraxin-3 and Fetuin-A in the diagnosis of prostate cancer.
前列腺癌是最常见的癌症类型之一，也是男性癌症相关死亡的主要原因之一。为了提高现有诊断方法并开发新的生物标志物以识别前列腺癌患者，人们进行了许多努力。根据当前文献，我们在本研究中优先选择了新的基于血清的生化标志物，如 Pentraxin-3、Fetuin-A 和 Sirtuin-7。
本研究共纳入 174 名年龄在 42-76 岁的患者。前列腺癌患者（n=38）纳入第 1 组，良性前列腺增生患者（n=136）纳入第 2 组。比较两组之间 Pentraxin-3、Fetuin-A 和 Sirtuin-7 水平。
患者的平均年龄为 61.9±7.6 岁（p=.001）。第 1 组和第 2 组的平均血清前列腺特异性抗原水平分别为 32.0±59.6（2.6-336）ng/mL 和 10.0±11.3（2.5-77.4）ng/mL（p=.029）。第 1 组的 Pentraxin-3 和 Fetuin-A 血清水平明显高于第 2 组（3.3±4.4ng/mL vs 1.8±2.4ng/mL，p=.002 和 466.8±11.0µg/mL vs 513.3±11.0µg/mL，p=.041）。第 1 组和第 2 组的 Sirtuin-7 血清水平无显著差异（分别为 12.7±8.2ng/mL 和 12.7±12.4ng/mL，p=.145）。
根据当前文献，Pentraxin-3、Fetuin-A 和 Sirtuin-7 可能对前列腺癌的诊断有效。本研究发现，Pentraxin-3 和 Fetuin-A 在诊断前列腺癌方面有显著差异。需要更大规模的前瞻性研究来确定 Pentraxin-3 和 Fetuin-A 在前列腺癌诊断中的重要性。
